We are delighted to announce an upcoming half-day symposium on Monday 15 May, which will kick start the Novel Insulins section of the Type 1 Diabetes Grand Challenge.
The symposium will provide a platform for researchers, policymakers, and stakeholders from academic and industry backgrounds to discuss the latest breakthroughs in insulin therapy.
Distinguished speakers from across the globe will be presenting at this event, sharing their valuable insights and expertise on the latest advances in new insulin research.
Our mission is to make a meaningful contribution to the field of insulin therapy, and we believe that this symposium represents a crucial step towards achieving our goal.
Dr Eleanor Kennedy, Novel Insulins Grand Challenge Lead said:
“We are thrilled to be hosting the Type 1 diabetes Grand Challenge Novel Insulins symposium, which promises to bring together a diverse range of researchers, policymakers, and stakeholders from around the world. With internationally renowned speakers and cutting-edge research, this symposium promises to be an exciting event that will drive innovation and progress in the treatment of diabetes.”
The Novel Insulins section of the Type 1 Diabetes Grand Challenge has an initial budget of £15 million. Future funding calls will focus on a broad community of scientists, with the aim of addressing the gaps, challenges and opportunities identified through the course of this symposium, and other relevant activities.
Please note that this symposium will be conducted solely in English, and no translation services will be provided. However, for the benefit of those who are unable to attend in person, we will be recording the event.
Sign up to the Type 1 diabetes Grand Challenge Novel Insulins symposium.